Literature DB >> 17869661

Prediction of radial distance of extraprostatic extension from pretherapy factors.

David J Schwartz1, Shomik Sengupta, David W Hillman, Daniel J Sargent, John C Cheville, Torrence M Wilson, Lance A Mynderse, Richard Choo, Brian J Davis.   

Abstract

PURPOSE: Extraprostatic extension (EPE) of tumor conveys an adverse prognosis in early-stage prostate cancer. Previous studies reported on the linear and radial distance of EPE (EPEr) as measured from the prostate edge. In this study, the correlation of the EPEr from a large whole mount prostatectomy series was determined with respect to the needle biopsy and prostatectomy specimen findings. METHODS AND MATERIALS: In a 24-month period, 404 patients underwent radical prostatectomy and the specimens were whole mounted. The preoperative records, biopsy findings, and EPEr from these specimens were evaluated.
RESULTS: The range of the EPEr distance was 0.0-5.7 mm. A three-category model was used that included 283 patients (70%) with no EPE, 59 (15%) with "near EPE" (range, 0.01-0.59 mm), and 62 (15%) with "far EPE" (>or=0.6 mm). Univariate analysis revealed that patient age and prostate volume did not correlate with EPEr, in contrast to all other factors evaluated. Multivariate analysis identified the preoperative serum prostate-specific antigen, the percentage of cancer in the biopsy cores, and clinical tumor stage as significant. However, the Gleason score was not associated with the EPEr. Greater discrimination was possible in estimating the probability of extension in the "near" category than in the "far" category.
CONCLUSION: EPEr is associated with the preoperative prostate-specific antigen level, percentage of cancer in the biopsy cores, and clinical tumor stage. These data might be useful in planning local therapies for prostate cancer, but additional studies identifying factors associated with EPEr beyond 3-5 mm could have relevance regarding the appropriate radiotherapeutic management strategies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17869661     DOI: 10.1016/j.ijrobp.2007.03.016

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Dose-escalated simultaneous integrated-boost treatment of prostate cancer patients via helical tomotherapy.

Authors:  M Geier; S T Astner; M N Duma; V Jacob; C Nieder; J Putzhammer; C Winkler; M Molls; H Geinitz
Journal:  Strahlenther Onkol       Date:  2012-02-26       Impact factor: 3.621

2.  Comparing CTVs for permanent prostate brachytherapy.

Authors:  C A Oton; L Blanco; L F Oton; S Moral
Journal:  Clin Transl Oncol       Date:  2014-10-29       Impact factor: 3.405

3.  Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: implications for prostate brachytherapy.

Authors:  Thomas J Pugh; Steven J Frank; Mary Achim; Deborah A Kuban; Andrew K Lee; Karen E Hoffman; Sean E McGuire; David A Swanson; Rajat Kudchadker; John W Davis
Journal:  Brachytherapy       Date:  2012-06-05       Impact factor: 2.362

4.  ERG rearrangement as a novel marker for predicting the extra-prostatic extension of clinically localised prostate cancer.

Authors:  L I Lu; Hao Zhang; Jun Pang; Guo-Liang Hou; Min-Hua Lu; Xin Gao
Journal:  Oncol Lett       Date:  2016-02-25       Impact factor: 2.967

5.  Prospective evaluation of microscopic extension using whole-mount preparation in patients with hepatocellular carcinoma: Definition of clinical target volume for radiotherapy.

Authors:  Weihu Wang; Xiaoli Feng; Tao Zhang; Jing Jin; Shulian Wang; Yueping Liu; Yongwen Song; Xinfan Liu; Zihao Yu; Yexiong Li
Journal:  Radiat Oncol       Date:  2010-08-23       Impact factor: 3.481

Review 6.  ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II.

Authors:  Nicholas G Zaorsky; Timothy N Showalter; Gary A Ezzell; Paul L Nguyen; Dean G Assimos; Anthony V D'Amico; Alexander R Gottschalk; Gary S Gustafson; Sameer R Keole; Stanley L Liauw; Shane Lloyd; Patrick W McLaughlin; Benjamin Movsas; Bradley R Prestidge; Al V Taira; Neha Vapiwala; Brian J Davis
Journal:  Adv Radiat Oncol       Date:  2016-10-20

7.  Dosimetry advantages of intraoperatively built custom-linked seeds compared with loose seeds in permanent prostate brachytherapy.

Authors:  Masahiro Inada; Masaki Yokokawa; Takafumi Minami; Kiyoshi Nakamatsu; Yasumasa Nishimura
Journal:  J Contemp Brachytherapy       Date:  2017-10-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.